ArticlePloS one2022
Epidemiological trends of Lassa fever in Nigeria, 2018-2021.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors.BMC public health · 2025Pooled it
- Local Knowledge of Land Use Effects on Human-Rodent Interfaces in Lassa-Endemic Nigeria.EcoHealth · 2026Article
- Lassa fever in the shadow of pregnancy - a case-control study of clinical presentation, risk factors and outcomes in Southern Nigeria.BMC pregnancy and childbirth · 2026Article
- Early Detection and Surveillance of Infectious Disease Outbreaks in Nigeria : Integrating Nigerian Pidgin English (NPE) into the EPIWATCHJournal of medical systems · 2026Article
- Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animals.Virus evolution · 2026Article
- Serological evidence of concurrent Lassa virus and SARS-CoV-2 exposure in Ghana- a cross-sectional study.BMC infectious diseases · 2025Article
- High Burden of Coinfections With Epidemic-Prone Pathogens Among Febrile Patients in Nigeria: A Multi-Pathogen Surveillance Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Socioeconomic and environmental predictors of lassa fever transmission in Lower Bambara Chiefdom, Kenema District, Eastern Sierra Leone.BMC public health · 2025Article
- Modelling the effects of climate and human factor on Lassa fever distribution in Ondo State Nigeria.International journal of biometeorology · 2025Article
- Estimation of Lassa fever incidence rates in West Africa: Development of a modeling framework to inform vaccine trial design.PLoS neglected tropical diseases · 2025Article
- A Review of the Epidemiology of Lassa Fever in Nigeria.Microorganisms · 2025Review
- Detection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon.Virology journal · 2025Article
- Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme ('ENABLE 1.5') - study protocol.BMJ public health · 2025Article
- Strengthening Outbreak Detection in Africa to Achieve the 7-1-7 Global Framework: Challenges and Opportunities.Public health reviews · 2025Review
- The resurgence of Lassa fever in Nigeria: economic impact, challenges, and strategic public health interventions.Frontiers in public health · 2025Article
- Drivers of Lassa fever in an endemic area of southwestern Nigeria (2017-2021): An epidemiological study.PloS one · 2025Article
- Descriptive epidemiology of Lassa fever, its trend, seasonality, and mortality predictors in Ebonyi State, South- East, Nigeria, 2018-2022.BMC public health · 2024Article
- Lassa fever in Nigeria: epidemiology and risk perception.Scientific reports · 2024Article
- Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study.BMC infectious diseases · 2024Article
- Lassa Fever: Critical Review and Prospects for Control.Tropical medicine and infectious disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLassa fever is a viral haemorrhagic fever endemic in Nigeria. Improved surveillance and testing capacity have revealed in an increased number of reported cases and apparent geographic spread of Lassa fever in Nigeria. We described the recent four-year trend of Lassa fever in Nigeria to improve understanding of its epidemiology and inform the design of appropriate interventions.
methodsWe analysed the national surveillance data on Lassa fever maintained by the Nigeria Centre for Diseases Control (NCDC) and described trends, sociodemographic, geographic distribution, and clinical outcomes. We compared cases, positivity, and clinical outcomes in the period January 2018 to December 2021.
resultsWe found Lassa fever to be reported throughout the year with more than half the cases reported within the first quarter of the year, a recent increase in numbers and geographic spread of the virus, and male and adult (>18 years) preponderance. Case fatality rates were worse in males, the under-five and elderly, during off-peak periods, and among low reporting states.
conclusionLassa fever is endemic in Nigeria with a recent increase in numbers and geographical distribution. Sustaining improved surveillance, enhanced laboratory diagnosis and improved case management capacity during off-peak periods should remain a priority. Attention should be paid to the very young and elderly during outbreaks. Further research efforts should identify and address specific factors that determine poor clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.